Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594044 | 0.85 | SLC6A2 (0.48) | SLC6A2SLC6A4HDAC8DRD2DRD3 | |
| SCHEMBL6980913 | 0.80 | CCR3 (0.52) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL7598890 | 0.77 | ACHE (0.56) | SLC6A2SLC6A4DRD3ACHE | |
| SCHEMBL7594049 | 0.76 | SLC6A2 (0.48) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL221425 | 0.75 | ACHE (0.63) | SLC6A2SLC6A4DRD2DRD4ACHE | |
| SCHEMBL7594547 | 0.74 | HDAC8 (0.44) | HDAC8ACHEUTS2R | |
| SCHEMBL7145587 | 0.73 | CHRM2 (0.67) | SIGMAR1 | |
| SCHEMBL7592724 | 0.72 | HDAC8 (0.46) | SLC6A2SLC6A4HDAC8ACHE | |
| SCHEMBL7592712 | 0.72 | HDAC8 (0.46) | SLC6A2SLC6A4HDAC8ACHE | |
| SCHEMBL15919881 | 0.72 | CHRM2 (0.58) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG L (US) | 2002-04-25 | — | — | US | disclosed |
| US-6303633-B1 | FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6124321-A | Heteroaryl amines as novel acetyl cholinesterase inhibitors | PFIZER INC (US) | 2000-09-26 | — | — | US | disclosed |
| US-5965574-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG LIANG (US) | 1999-10-12 | — | — | US | disclosed |
| US-5574046-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | PFIZER INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1993007140-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | PFIZER INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | ACHE, BCHE, CHAT | SLC6A2 1217/4885SLC6A4 2681/4885HDAC8 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.